EUCTR2005-002126-64-DK进行中（未招募）1 期
A Randomized Phase II Study to Determine Potential Predictive Markers of Response to MDX-010 (BMS-734016) in Patients with Unresectable Stage III or IV MalignantMelanoma.Revised Protocol 2 dated 09-Dec-2005 incorporating Protocol Amendments 02 & 03. And Protocol Amendment 1 dated 20-Jul-2005.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Target population
- •a) Able to comply with visits/procedures required by the protocol
- •b) Life expectancy of at least 4 months.
- •c) ECOG performance status score 0-1. (See Appendix 4 of the protocol)
- •d) Histologic or cytologic diagnosis of unresectable Stage III or IV malignant
- •melanoma (excluding ocular melanoma).
- •e) A pre- and post-treatment fresh core or excision tumor biopsy must be provided
- •for biomarker and predictive marker analyses. It is preferred that the biopsies are
- •obtained from the same organ. Note: Site of tumor biopsy should not be the only
- •site of measurable disease.
- •f) Measurable disease as defined in Section 3.3.2.2 of the protocol.
- •g) Required values for initial laboratory tests (see protocol for test details)
- •h) At least 4 weeks must have elapsed since the last chemotherapy, immunotherapy,
- •hormonal therapy, radiotherapy or major surgery and the beginning of protocol
- •therapy. At least 6 weeks for nitrosoureas, mitomycin C and liposomal doxorubicin.
- •i) Toxicity related to prior therapy must either have returned to = grade 1, baseline,
- •or been deemed irreversible.
- •3) Age and Sex
- •a) Men and women, ages 18 and above.
- •Women of childbearing potential (WOCBP) must be using an adequate method of
- •contraception to avoid pregnancy throughout the study in such a manner that the
- •risk of pregnancy is minimized. Suggested precautions should be
- •used to minimize the risk or pregnancy for at least 1 month before dosing, and
- •while women are on study and for up to 12 weeks after last dose of study drug.
- •WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation
- •or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea
- •= 12 consecutive months; or women on hormone replacement therapy (HRT) with
- •documented serum follicle stimulating hormone (FSH) level > 35mIU/mL]. Even women who are using oral, implanted or injectable contraceptive hormones or
- •mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential.
- •WOCBP must have a negative pregnancy test (minimum sensitivity 25 IU/L or
- •equivalent units of HCG) within 72 hours prior to the start of study medication.
- •Men must be willing and able to use an acceptable method of birth control, for at
- •least 3 months after completion of the study, if their sexual partners are WOCBP.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Sex and Reproductive Status
- •a) WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 12 weeks after the study;
- •b) WOCBP using a prohibited contraceptive method;
- •c) Women who are pregnant or breastfeeding;
- •d) Women with a positive pregnancy test on enrollment or prior to study drug administration;
- •e) Sexually active fertile men who are unwilling or unable to use an acceptable method of birth control, for the entire study period and for at least 3 months after completion of the study, if their sexual partners are WOCBP.
- •2) Target Disease Exclusion
- •a) Any other malignancy from which the patient has been disease-free for less than
- •5 years, with the exception of adequately treated and cured basal or squamous cell
- •skin cancer, superficial bladder cancer, carcinoma in situ of the cervix;
- •b) Ocular melanoma.
- •3) Medical History and Concurrent Diseases
- •a) Active, untreated central nervous system (CNS) metastasis (including metastasis
- •identified during screening MRI or contrast CT);
- •b) Autoimmune disease: Patients with a history of Inflammatory Bowel Disease are
- •excluded from this study as are patients with a history of autoimmune disease (e.g. Systemic Lupus Erythematosus, vasculitis, infiltrating lung disease) whose possible progression during treatment would be considered by the Investigator to be unacceptable. Patients with a history of well-controlled and/or clinically manageable autoimmune disease (e.g. vitiligo, well-controlled thyroid disease, mild psoriasis) may be considered for inclusion in consultation with the CRO;
- •c) Any underlying medical condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of
- •adverse events, such as a condition associated with frequent diarrhea;
- •d) Positive screening tests for HIV, HepB, and HepC. If positive results are not indicative of true active or chronic infection, the patient can be admitted after discussion with and agreement by the BMS Medical Monitor;
- •e) Uncontrolled or significant cardiovascular disease including
- •- myocardial infarction within 12 months
- •- uncontrolled angina within 6 months
- •- Class III-IV New York Heart Association (NYHA) congestive heart failure
- •- diagnosed or suspected congenital long QT syndrome
- •- any history of clinically significant ventricular arrhythmias (such as
- •ventricular tachycardia, ventricular fibrillation, or torsade de pointes). Any
- •patient with a history of any arrhythmia should be discussed with the BMS Medical Monitor prior to entry into the study
- •- prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
- •- any history of second or third degree heart block (may be eligible if currently have a pacemaker)
- •4) Prohibited Therapies and/or Medications
- •a) Prior exposure to an anti-CTLA4 antibody.
- •b) Use of any immunosuppressing treatments including corticosteroids (patients on
- •stable doses of hormone replacement therapy are exempt), cyclosporine, mycophenolate mofetil (CellCept), chorg.apache.struts.taglib.html.TOKEN=d2b88d7633fb5b40b115c66102d264ec
研究者
相似试验
进行中（未招募）
不适用
A Randomized Phase II Study to Determine Potential Predictive Markers of Response to MDX-010 BMS-734016 in Patients with Unresectable Stage III or IV Malignant Melanoma - NDMalignant unresectable melanoma, stage III or IV.MedDRA version: 6.1Level: HLTClassification code 10027156EUCTR2005-002126-64-ITBRISTOL-M.SQUIBB90
进行中（未招募）
不适用
A randomized trial to identify markers for personalized treatment in patients treated with bevacizumab and paclitaxel for advanced breast cancerAdvanced breast cancerEUCTR2012-003743-30-SEKarolinska University Hospital
进行中（未招募）
1 期
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies. A Multi-Center Trial. - 1938.00Hematologic malignanciesEUCTR2005-003305-90-DKFred Hutchinson Cancer Research Center150
进行中（未招募）
不适用
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies. A Multi-Center Trial. - 1938.00Hematologic malignanciesEUCTR2005-003305-90-DEFred Hutchinson Cancer Research Center150
进行中（未招募）
1 期
A study to assess the schemas of retreatment with Lutathera® in patients with new progression of intestinal well-differentiated neuroendocrine tumor.EUCTR2021-001306-30-FRInstitut Régional du Cancer de Montpellier146